Pangenome-guided immunoinformatics design and in silico characterization of a multi-epitope vaccine candidate against Acinetobacter baumannii with nanoparticle assembly potential.
This in silico characterized vaccine construct represents a promising candidate requiring experimental validation against A. baumannii infections, and computationally design and in silico characterize a self-assembling nanoparticle vaccine with dual adjuvants.
Abstract
Acinetobacter baumannii is a critical multidrug-resistant pathogen causing severe healthcare infections with high mortality, yet no licensed vaccine exists. This study aims to identify universally conserved surface antigens through pangenome analysis, predict immunogenic epitopes using integrated machine learning, and computationally design and in silico characterize a self-assembling nanoparticle vaccine with dual adjuvants. A computational framework integrating pangenome analysis of 712 complete genomes, epitope prediction, and structural vaccinology was employed to design a multi-epitope nanoparticle vaccine candidate for experimental evaluation. Pangenome analysis identified 3894 core genes with 42 outer membrane proteins, prioritizing OmpA, BamA, and OmpW as antigen targets. Protein language models predicted conformational B-cell epitopes, while NetMHCpan-4.2 predicted T-cell epitopes across 125 HLA alleles. The final construct (AB-VAX-01, 289 amino acids) incorporates 15 epitopes fused with dual adjuvants (RS09 TLR4 and cGAMP STING agonists) and a foldon domain for nanoparticle assembly. Microsecond molecular dynamics simulations with replicates demonstrated stability with TLR4 and STING. Conservation analysis across all 712 genomes showed 96.2-100% epitope identity. Immune simulations predicted Th1-biased responses with 94.2% global population coverage. In silico cloning confirmed favorable codon adaptation parameters. This in silico characterized vaccine construct represents a promising candidate requiring experimental validation against A. baumannii infections.
The two proposed multi-epitope mRNA vaccine constructs showed promising immunogenic, safety, and structural properties in silico, highlighting their potential as candidate vaccines against HMPV.
E. K. Oladipo, James Akinwumi Ogunniran, Oluwaseyi Samuel Akinpelu et al.· Discover Immunity· 1 citation
The designed MEV and identified immunogenic targets represent promising vaccine candidates against S. maltophilia, offering safer and more specific therapeutic avenues, and nine novel drug targets were predicted for S. maltophilia, providing new therapeutic insights.
Safoura Moradkasani, Narjes Noori Goodarzi, M. Beig et al.· Journal of Genetic Engineeri...· 1 citation
The proposed multi-epitope vaccine shows promising immunological and structural properties, supporting its potential against S. typhimurium, pending experimental validation.
Mohammed Naveez Valathoor, A. P. Rajan· Scientific Reports· 0 citations
This study presents a structurally optimized and validated multiepitope vaccine candidate against the emerging Batai orthobunyavirus, identifying a promising vaccine candidate for further investigation; however, its immunogenicity, safety, and protective efficacy before further vaccine development can be considered.
M. A. Alwaili, N. Al‐Hoshani, Huda A Alqahtani et al.· Pharmaceuticals· 0 citations
The results highlight the potential of the proposed multi-epitope construct as a promising vaccine candidate against HCMV, however, experimental validation is essential to confirm its immunogenicity, safety, and translational applicability.
O. P. Emmanuel, M. N. Y. Sandrine, Bilanda Danielle Claude et al.· Scientific Reports· 0 citations